Literature DB >> 11313922

Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins.

R J Olsen1, S H Hinrichs.   

Abstract

Specific chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors. The combination of different domains from unrelated genes results in chimeric proteins believed to play a key role in the neoplastic process. The EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma and Ewing's Sarcoma, respectively, were utilized to study the comparative effect of the EWS component on two different DNA binding partners. A potential regulatory site within the EWS IQ domain at serine266 was identified, and studies were performed to demonstrate that EWS is phosphorylated in cells and phosphorylation of serine266 regulates transcriptional activity. Mutational analysis showed that elimination of phosphorylation significantly reduced DNA binding activity by EMSA and reporter activation in luciferase assays, whereas phosphorylation mimicry resulted in a partial restoration to wild-type levels. Phosphorylation was also observed to mediate cellular compartmentalization. These studies confirm that IQ domain phosphorylation regulates the transcriptional activity of exogenous EWS/ATF1 and EWS/FLI1 and suggests that post-translational modifications may potentiate the neoplastic behavior of fusion proteins in general. Since the IQ domain is incorporated into only a subset of fusion transcripts, these findings may provide insight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313922     DOI: 10.1038/sj.onc.1204268

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.

Authors:  Cristina R Antonescu; Sylvia J Tschernyavsky; James M Woodruff; Achim A Jungbluth; Murray F Brennan; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

2.  A transcription assay for EWS oncoproteins in Xenopus oocytes.

Authors:  King Pan Ng; Felix Cheung; Kevin A W Lee
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

3.  Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.

Authors:  Vittorio Caropreso; Emad Darvishi; Thomas J Turbyville; Ranjala Ratnayake; Patrick J Grohar; James B McMahon; Girma M Woldemichael
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

Review 4.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

5.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

6.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

Review 7.  The potential for molecular therapeutic targets in Ewing's sarcoma.

Authors:  Nancy R McAllister; Stephen L Lessnick
Journal:  Curr Treat Options Oncol       Date:  2005-11

8.  CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis.

Authors:  Salemiz Sandoval; Martina Pigazzi; Kathleen M Sakamoto
Journal:  Adv Hematol       Date:  2009-08-27

9.  RGG-boxes of the EWS oncoprotein repress a range of transcriptional activation domains.

Authors:  Deepa Alex; Kevin A W Lee
Journal:  Nucleic Acids Res       Date:  2005-03-02       Impact factor: 16.971

10.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.